Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.35 USD

9.35
1,634,358

+0.41 (4.59%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Horizon Therapeutics (HZNP) Looks Good: Stock Adds 5.3% in Session

Horizon Therapeutics (HZNP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.

Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor

Zacks.com featured highlights include: Boise Cascade, Century Communities, Emergent BioSolutions and Deckers Outdoor

Top Ranked Momentum Stocks to Buy for August 7th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons Why

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q2 revenues increase year over year.

Emergent BioSolutions' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.

Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.

Nitish Marwah headshot

4 Solid Momentum Picks Screened on Driehaus Strategy

Investors who have the tendency to take a high level of risk can choose momentum stocks.

Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss

Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance

Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.

Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.